Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Age-dependent disease tolerance to SARS-CoV-2 infection

Created on 02 Jul 2026

Authors

Trikha Rastogi, S., Mesquita, M., Fonseca, D. M., Salazar, S., Cardoso, S., Faisca, P., Drotleff, B., Alenquer, M., Lone, J.-C., Miguel, V., Sancho, D., Herrero, L., Paixao, T., Amorim, M. J., Jentho, E., Graca, L., Kitoko, J. Z., Soares, M. P.

Abstract

Disease tolerance limits infectious disease severity through tissue damage control mechanisms that do not target pathogens directly. Here we demonstrate that age-dependent decline in adipose tissue lipolysis compromises disease tolerance to SARS-CoV-2 infection. Young adult mice exhibited robust adipocyte lipolysis and 80% survival, whereas old mice showed impaired adipocyte lipolysis and only 20% survival. Genetic repression of adipocyte lipolysis eliminated this age-dependent survival advantage without affecting viral titers, revealing that adipocyte lipolysis is essential for disease tolerance to SARS-CoV-2 in young adults. Impaired adipocyte lipolysis in aged mice was associated with a plasma lipidomic signature that predicts COVID-19 severity and mortality in three independent human cohorts. Mechanistically, adipocyte lipolysis provides free fatty acids (FFA) to support bone marrow emergency myelopoiesis, through CD36- and CPT1-dependent FFA cellular uptake and mitochondrial import, respectively. Bone marrow derived monocytes migrate to the lung via CCL2/CCR2-dependent mechanism where they enforce an immune-metabolic communication network with parenchymal cells to sustain lung structure and function. This circuit is not required to confer protection against influenza infection, revealing pathogen-specific disease tolerance mechanisms. These findings reveal adipose tissue catabolism as a central age-dependent factor responsible for exacerbated COVID-19 mortality in aged populations.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 02 Jul 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 2
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement